Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples. Immunogen corresponding to Recombinant Fragment Protein within SARS-CoV-2 S.
Constituents: 99.9% PBS
ELISA | |
---|---|
Recombinant fragment - SARS-CoV-2 | Tested |
SARS-CoV-2 | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - SARS-CoV-2 | Dilution info 1/5000.00000 - 1/10000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info - | Notes - |
Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed:32142651, PubMed:32155444, PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed:34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed:32075877, PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294, PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed:32817270). Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein
Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples. Immunogen corresponding to Recombinant Fragment Protein within SARS-CoV-2 S.
Constituents: 99.9% PBS
Purity: >95%. Endotoxin level: < 0.01 EU/ug.
The SARS CoV-2 Spike N-terminal domain (NTD) also known as the receptor-binding domain (RBD) is a critical element of the viral spike protein responsible for mediating virus entry into host cells. The NTD is a portion of the spike glycoprotein that is approximately 180 kDa in mass. It is located on the surface of the virus and plays a role in immune response evasion by the virus. The Spike NTD is expressed as part of the trimeric spike protein complex on the envelope of the virus interacting with cell surface receptors to facilitate viral entry and infection.
The Spike NTD engages in the initial interactions with host cells alongside other domains of the spike protein such as the S1 and S2 subunits. It functions in recognizing and binding to host cell receptors like angiotensin-converting enzyme 2 (ACE2) though it specifically contributes to the virus's ability to shield critical binding motifs from neutralizing antibodies. The spike protein including the NTD forms a complex critical for the conformational changes necessary for membrane fusion between the virus and host cells advancing viral infectivity and transmission.
The Spike NTD of SARS CoV-2 operates within the viral entry and replication pathways. In the entry pathway the NTD interacts with cellular proteases that prime the spike protein for fusion. It is also tied to the host immune evasion pathway engaging with immune system checkpoints and preventing effective antibody neutralization. Relationships with proteins such as furin and TMPRSS2 are notable as these proteins assist in priming and activating the spike protein facilitating the fusion process.
SARS CoV-2 and its Spike NTD are directly associated with COVID-19. This domain is significant in understanding the virus's infectivity and immune resistance impacting the severity and spread of the disease. Mutations in the NTD have also been linked to the emergence of new variants with altered transmissibility and immune escape properties. The Spike NTD is connected to other spike protein domains through the disease as changes in one domain can affect the overall function and pathogenic profile of the virus.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Direct ELISA shows that ab289797 can bind to immobilized Spike NTD (EC50 = 101.5 ng/ml)
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com